Preclinical Biodistribution and Toxicology Packages for Venture-Backed Gene Therapy Startups

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Biodistribution and Toxicology Packages for Venture-Backed Gene Therapy Startups

AAV Biodistribution and Toxicology Studies for IND Submission

CELL & GENE | RNA | BIOLOGICS

Mapping Vector Fate to De-Risk Clinical Translation.

    How does Franklin Biolabs address species-specific differences in AAV tropism during study design?

    We integrate vector biology directly into our study design. Recognizing that glycan presentation and receptor availability can differ significantly across species, we recommend multi-species evaluations or the use of models with demonstrated translational relevance. Our approach focuses on generating a data matrix that allows for informed extrapolation to human clinical outcomes, rather than relying on a single model organism.

    What is the standard tissue panel for non-target tissue biodistribution analysis?

    Our core panel aligns with FDA and EMA guidance, typically including the central nervous system, heart, lungs, liver, kidney, spleen, gonads, and injection site. We expand this panel based on the vector serotype, promoter specificity, and known biology of the therapeutic target. For novel capsids or delivery platforms, we recommend a more extensive screening panel during initial pilot studies.

    How does your GxP framework ensure data integrity for our IND filing?

    All IND-enabling studies are conducted within our robust GxP quality system, which governs every phase from protocol development to final reporting. This includes validated assay methodologies, comprehensive equipment qualification, secure chain of custody for all samples, and rigorous data review processes. This framework ensures that the resulting data package is audit-ready and meets global regulatory expectations for integrity and traceability.

    Which molecular assays are standard for quantifying vector persistence and expression?

    Our primary quantification method for vector DNA biodistribution is droplet digital PCR (ddPCR) due to its high precision and sensitivity, supplemented by qPCR for broader screening. For transgene expression, we utilize RT-qPCR to measure mRNA levels and provide custom protein quantification assays (e.g., ELISA, Western Blot) and advanced Histology services.

We provide the framework for designing and executing IND-enabling biodistribution and toxicology studies for AAV-based gene therapies. Venture-backed sponsors receive comprehensive data packages that characterize vector safety, persistence, and activity profiles. Our programs are structured to deliver a complete IND-ready dataset within an 18-24 month timeline, leveraging validated bioanalytical methods and a GxP-compliant operational backbone to support regulatory submissions.

Defining the Preclinical Data Package for AAV Vectors

Predicting the in vivo fate of an AAV vector is a primary objective of any preclinical program. The distribution profile directly informs both the efficacy and safety assessment, providing regulators with a clear rationale for the proposed clinical starting dose and risk mitigation plan. A robust study must account for the vector’s inherent tropism, potential for non-target tissue biodistribution, and long-term persistence.

Our study designs move beyond simple quantification. We focus on generating a cohesive dataset that links vector concentration in a given tissue to functional outcomes, such as transgene expression and observable phenotype. This approach provides a stronger foundation for regulatory review and clinical trial design.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Translating Vector Engineering Insights into Preclinical Strategy

Advances in capsid engineering allow for the modulation of tissue tropism to enhance therapeutic effect and minimize off-target activity. As demonstrated in AAV9 engineering studies, subtle modifications to the capsid can significantly alter glycan binding, leading to divergent biodistribution profiles between preclinical species and, presumably, humans (PMID: 39001819). This highlights the need for preclinical models that accurately reflect human biology or for study designs that account for these potential cross-species differences.

Similarly, comprehensive safety and efficacy evaluations across multiple relevant species provide a powerful tool for de-risking a program. Data from well-controlled studies, such as those evaluating AAVhu68 gene therapy, establish a favorable safety profile that builds confidence for first-in-human trials (PMID: 35333110). Our programs are designed to generate this type of conclusive, multi-species evidence.

Integrated Biodistribution and Toxicology Packages

Franklin Biolabs provides standardized and customizable packages to support gene therapy developers from early discovery through IND submission. Operating from our >100,000 sq ft facility, our teams deliver high-fidelity intelligence tracking therapeutic delivery. This commitment to quality has supported a 100% IND success rate for our clients’ programs since 2019, with the Franklin Biolabs brand itself having launched in 2024.

Our services are built on a GxP framework to ensure regulatory compliance.

Service Component Standard Package IND-Enabling Package
Study Design Non-GxP, exploratory GxP-compliant, IND-focused
Vector Biodistribution qPCR/ddPCR (vector DNA) Validated qPCR/ddPCR assays
Transgene Expression RT-qPCR (mRNA) Validated RT-qPCR & Protein Assays
Histology H&E staining Full pathology report, IHC/ISH
Toxicology Clinical observations, body weights Full GxP-compliant toxicology assessment
Reporting Research report IND-ready final report

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

Commitment to Animal Welfare

Our animal care and use programs are designed to meet or exceed the standards set by organizations such as AAALAC and the USDA. We strictly follow the principles of the 3Rs: Reduce, Refine, and Replace.

By integrating advanced bioanalytical techniques with rigorous GxP oversight, we provide gene therapy developers with the definitive data needed to advance their programs to the clinic with confidence.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities